Hera BioLabs, a service and technology provider with novel genetic engineering products, and Charles River Laboratories International Inc. have signed a global license agreement to commercialize Hera’s SRG rat (OncoRat), the first highly immunocompromised rat model, validated for xenograft studies in oncology and infectious disease research applications.
 
Under this new collaborative agreement, Charles River will breed, distribute, sell, and market the SRG rat directly to the preclinical research community, while Hera will focus on providing services utilizing the model. 
 
Hera BioLabs CEO, Dr. Mike Schlosser, commented, “We are very pleased to be working with Charles River, a company known for delivering high quality products and services for drug discovery and development. Their confidence in Hera’s SRG rat as an emerging go-to model is evidenced by this collaboration and highlights the transformative technology offered by Hera. This agreement creates substantial opportunities for Hera BioLabs to grow our SRG rat franchise in conjunction with Charles River’s portfolio expansion, bringing high quality research models to investigators world-wide.”
 
Colin Dunn, corporate senior vice president of Charles River’s Research Model and Services, said, “We are thrilled to add the SRG rat to our portfolio of research models, which will expand the availability and distribution of this impactful oncology model for preclinical research.”